Thermo Fisher ScientificTMO
TMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
Employees: 122,000
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
47% more first-time investments, than exits
New positions opened: 170 | Existing positions closed: 116
6% more capital invested
Capital invested by funds: $197B [Q2] → $208B (+$11.4B) [Q3]
4% more funds holding in top 10
Funds holding in top 10: 111 [Q2] → 115 (+4) [Q3]
3% more repeat investments, than reductions
Existing positions increased: 1,009 | Existing positions reduced: 977
1% more funds holding
Funds holding: 2,498 [Q2] → 2,519 (+21) [Q3]
4.69% less ownership
Funds ownership: 93.42% [Q2] → 88.73% (-4.69%) [Q3]
13% less call options, than puts
Call options by funds: $1.59B | Put options by funds: $1.84B
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$605
6%
upside
Avg. target
$643
12%
upside
High target
$718
25%
upside
10 analyst ratings
7 positive
70%
3 neutral
30%
0 negative
0%
Morgan Stanley Tejas Savant 36% 1-year accuracy 5 / 14 met price target | 13%upside $647 | Overweight Maintained | 13 Jan 2025 |
Scotiabank Sung Ji Nam 60% 1-year accuracy 12 / 20 met price target | 6%upside $605 | Sector Perform Initiated | 23 Dec 2024 |
B of A Securities Derik De Bruin 63% 1-year accuracy 12 / 19 met price target | 15%upside $660 | Buy Maintained | 13 Dec 2024 |
Bernstein Eve Burstein 57% 1-year accuracy 4 / 7 met price target | 8%upside $620 | Market Perform Maintained | 24 Oct 2024 |
RBC Capital Conor McNamara 26% 1-year accuracy 10 / 38 met price target | 25%upside $718 | Outperform Maintained | 24 Oct 2024 |
Financial journalist opinion
Based on 9 articles about TMO published over the past 30 days
Positive
Zacks Investment Research
6 hours ago
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Positive
Zacks Investment Research
9 hours ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Neutral
Business Wire
6 days ago
Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral Therapies
WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, in which Thermo Fisher will provide global clinical research and commercial manufacturing services to Lyndra for its long-acting oral therapies. Lyndra's long-acting oral therapies, including lead investigational product oral weekly risperidone (.
Neutral
CNBC Television
1 week ago
Final Trades: Reddit, Delta, Thermo Fisher and Eli Lilly
The Investment Committee give you their top stocks to watch for the second half.
Neutral
Seeking Alpha
1 week ago
Thermo Fisher Scientific Inc. (TMO) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Thermo Fisher Scientific Inc. (NYSE:TMO ) 43rd Annual J.P. Morgan Healthcare Conference Call January 14, 2025 11:15 AM ET Company Participants Marc Casper - Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Perfect.
Negative
Zacks Investment Research
1 week ago
Macroeconomic Woes, Competition Weigh on TMO's Stock Performance
The industry-wide trend of difficult macroeconomic conditions is creating a challenging business environment for Thermo Fisher.
Neutral
Business Wire
1 week ago
Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the UK Biobank Pharma Proteomics Project (UKB-PPP) has selected its Olink® Explore Platform to support the world's largest human proteomics study of its kind. UKB-PPP aims to analyze more than 5,400 proteins from 600,000 samples to fuel the discovery of new protein biomarkers that can be used to predict, diagnose and treat diseases. “Studies on the human proteome are.
Neutral
Business Wire
2 weeks ago
Thermo Fisher Scientific to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world lead.
Neutral
Business Wire
2 weeks ago
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 30, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outs.
Neutral
Business Wire
1 month ago
Knipper Health Announces Transfer of Commercial Sample Management Business from Thermo Fisher Scientific
LAKEWOOD, N.J.--(BUSINESS WIRE)--Knipper Health, Inc., the largest supplier of end-to-end pharmaceutical healthcare marketing services and solutions in the U.S. serving the biopharmaceutical and medical industries, announced today the Company has been assigned the assets of Patheon Pharma Services sample and fulfillment services, from Thermo Fisher Scientific, located in Memphis TN. Included in the assignment, Knipper will retain all colleagues, as well as the Memphis site, along with all custo.
Charts implemented using Lightweight Charts™